Abstract: Peroxycarboxylic acid compositions having reduced hydrogen peroxide content are generated according to the invention, having enhanced antimicrobial efficacy. Simultaneously, a stable hydrogen peroxide and active oxygen coordinating compound complex is generated and has utility as a recycled bleaching component. In particular, methods of using an active oxygen coordinating compound to selectively and non-destructively remove hydrogen peroxide are provided. Preferred active oxygen coordinating compounds suitable for use with the peroxycarboxylic acid compositions include nitrogen-containing compounds, preferably urea, urea copolymers and/or derivatives, PVP, PVP copolymers and/or derivatives, and/or inorganic carbonates.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present invention relates to novel antiviral compounds which are covalently attached to solid, macro surfaces. In another embodiment, the invention relates to novel antiviral compositions including a polymeric material and, embedded therein, an antiviral compound. In other embodiments, the invention relates to making a surface antiviral and making a polymeric material antiviral.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject.

Abstract: Provided are a novel titania fine-particle composite which has high transparency, high stability, and high ultraviolet-absorbing power and excellent redispersibility, and skin-care external preparations which contain the titania fine-particle composite and exert high ultraviolet protective effect. The titania fine-particle composite can be produced by adding one or more selected from among carboxylic acids and carboxylic acid derivatives represented by general formula (1), and polymers containing the carboxylic acids or carboxylic acid derivatives as a constituent monomer to an aqueous acid dispersion of titania fine particles, and neutralizing the resulting dispersion with an alkali to form a titania fine-particle composite composed of titania fine particles functioning as cores and the carboxylic monomer or polymer deposited on the surface of the cores.

Abstract: The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning wounds.

Abstract: Materials with high levels of unsaponifiable matter, such as extracts from plants, produce hydrolysates with unique properties. The application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6 weight percent of the material), produces a product with properties significantly different from those products resulting from the conventional saponification of materials with less than 6 weight percent of unsaponifiables. The hydrolysates of the present invention are substantive, resisting both physical and aqueous-based removal from skin and hair, exhibit a unique surfactant property, and are not foaming agents with water. Hydrolysates according to the present invention may be used to enhance the performance of cosmetics and pharmaceuticals.

Abstract: A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: The invention relates to the use of compounds of the formula (I), in which R1, R2, m and n have the meanings indicated in the Claims, and/or physiologically acceptable salts, tautomers, stereoisomers and/or solvates thereof, including mixtures thereof in all ratios, for the inhibition of tyrosinase and for lightening the skin. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of pigment disorders of the skin. The invention furthermore relates to preparations comprising the compounds of the formula (I) in combination with at least one further active compound and to a process for the preparation of the preparations by mixing the compounds of the formula (I) with a vehicle which is physiologically acceptable for topical applications.

Abstract: The present invention provides an aqueous composition and its use for dissolving blood clots in vivo or in clinical or research samples in vitro, said composition comprising at least one chaotropic agent, at least one chelating agent that complexes iron if the chaotropic agent does not complex iron and at least one surface-active emulsifier, the composition being buffered near pH 7.4. The process of dissolving the clot with the aqueous composition is advantageous because it is simple, inexpensive, rapid and can be applied in a variety of contexts, including basic research and clinical situations.

Abstract: The present invention relates, in one aspect, to an adduct of formula O-PF-A, in which O is an oil; PF is a perfluoropolyether phosphate (PFPE phosphate); A is at least one substance selected from: (X) a water-soluble polyhydroxylated substance and (Y) a water-insoluble inorganic substance and to topical applications thereof in particular in the cosmetic and pharmaceutical field.

Abstract: Implantable medical devices including a coating having a bioactive agent and a poly(ester amide) polymer. Methods of forming these coatings are also described.

Abstract: Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein.

Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

Abstract: Described herein are compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and anti-bacterial applications of such compositions. The sNAG nanofibers may be formulated into compositions for the prevention and/or treatment of bacterial infections and diseases associated with such infections. Regimens employing such compositions are also described.

Abstract: The present invention relates to silicone compounds which have photoprotective properties and personal care compositions comprising the same. The present inventors, in developing a sunscreen that gives protection against both UV radiation and visible radiation, found that when a certain moiety generally occurring in nature i.e. hydroxyanthraquinone having uv-visible absorption activity are attached to crosslinked silicone polymers they provide not only the desired photoprotection but also excellent spreadability on skin.

Abstract: The invention relates to a method for producing medicaments that contain vardenafil hydrochloride, essentially as trihydrate in solid form, and to medicaments that can be obtained according to this method.

Abstract: The present invention relates to hair care and personal care compositions which contain an acrylic copolymer which is polymerized in the presence of at least two different classes of crosslinking monomers. The polymer functions both as a fixative/film former and a thickening agent for hair styling and personal care compositions in which it is contained. The copolymer exhibits advantageous fixative, film forming and rheological gel properties.